Related Experiment Videos
[Tuberculosis among patients treated with TNF-alpha blockers]
Inbal Fuchs-Polychuck1, Lone Sølling Avnon, Mahmoud Abu-Shakra
1Department of Family Medicine, Soroka University Medical Center, Ben-Gurion University of the Negev Beer Sheva, Israel.
Abstract:
Several reports have indicated a relationship between reactivation of latent tuberculosis infection (LTBI) and treatment with tumor necrosis factor alpha (TNF) blocking agents. These biologic drugs have demonstrated high efficacy in the treatment of chronic inflammatory diseases. Several guidelines have been published worldwide suggesting pretreatment screening strategies for latent tuberculosis in candidates for TNF-blocking treatment, as well as a regimen for prophylactic therapy if latent tuberculosis is indeed diagnosed. There are considerable variations among the different guidelines. This review summarizes currently available data on the risk of infection and particularly, the increased risk profile for tuberculosis in patients treated with TNF-blocking agents. The role of TNF alpha blockers in the pathogenesis of tuberculosis and the existing protocols that have been formulated in order to minimize the risk of tuberculosis reactivation during TNF blockade are also outlined.
Insights
Tumor necrosis factor alpha (TNF) blocking agents can increase the risk of latent tuberculosis infection (LTBI) reactivation. Guidelines recommend screening and prophylactic therapy for patients starting TNF blockade.
Area of Science:
- Immunology
- Infectious Diseases
- Pharmacology
Context:
- Biologic drugs targeting tumor necrosis factor alpha (TNF) are effective for chronic inflammatory diseases.
- TNF blockers are associated with an increased risk of tuberculosis (TB) reactivation.
- Existing international guidelines offer strategies for TB screening and prophylaxis in patients receiving TNF inhibitors.
Purpose:
- To review the risk of TB reactivation in patients treated with TNF blockers.
- To outline the role of TNF-alpha in TB pathogenesis.
- To summarize current protocols for minimizing TB risk during TNF blockade.
Summary:
- Treatment with TNF-blocking agents is linked to a higher risk of latent tuberculosis infection (LTBI) reactivation.
- This review examines the specific risks and the role of TNF-alpha in TB pathogenesis.
- It also details current strategies and guidelines for preventing TB reactivation in patients undergoing TNF blockade therapy.
Impact:
- Informing clinical practice regarding the safe use of TNF blockers.
- Highlighting the need for standardized TB screening and management protocols.
- Contributing to patient safety by mitigating the risk of severe infectious complications.
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Tuberculosis